Linked Life Data

12782020

Source:http://linkedlifedata.com/resource/pubmed/id/12782020

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12782020rdf:typepubmed:Citationlld:pubmed
pubmed-article:12782020lifeskim:mentionsumls-concept:C0027051lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0332161lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0597198lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0456389lld:lifeskim
pubmed-article:12782020lifeskim:mentionsumls-concept:C0388640lld:lifeskim
pubmed-article:12782020pubmed:issue3lld:pubmed
pubmed-article:12782020pubmed:dateCreated2003-6-3lld:pubmed
pubmed-article:12782020pubmed:abstractTextTNF-alpha is a proinflammatory cytokine, abundantly expressed after myocardial infarction. It has been suggested that it exhibits myocardial suppressive and cytotoxic effects. AG-556 is a tyrosine kinase inhibitor synthesized based on its ability to reduce TNF-alpha production and cell toxicity, and to improve experimental models mediated by TNF-alpha (i.e., peritontitis and experimental autoimmune encephalomyelitis). Daily, for 7 days, rats were injected ip with either AG-556 dissolved in DMSO or with the control vehicle. Infarct size was determined in the hearts as well as in fibrous scar formation. Cardiac TNF-alpha expression was evaluated by ELISA and immunohistochemistry. Functional hemodynamic parameters were evaluated employing echocardiography prior to sacrifice. AG-556 treatment reduced MI size at 7 days with a parallel effect on fibrous tissue formation. TNF-alpha production by splenocytes was reduced upon AG-556 treatment, whereas no differences were evident between the groups with regard to myocardial cytokine expression. AG-556 attenuated the decrease in fractional shortening at the expense of preserving end systolic diameter. AG-556 has proven beneficial in reducing myocardial infarct size and attenuated consequent hemodynamic deterioration in the rat model. If reconfirmed, AG-556 may be of potential clinical use in post-MI patients.lld:pubmed
pubmed-article:12782020pubmed:languageenglld:pubmed
pubmed-article:12782020pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782020pubmed:citationSubsetIMlld:pubmed
pubmed-article:12782020pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782020pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782020pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782020pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782020pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782020pubmed:statusMEDLINElld:pubmed
pubmed-article:12782020pubmed:monthJunlld:pubmed
pubmed-article:12782020pubmed:issn0014-4800lld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:GeorgeJacobJlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:KerenGadGlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:LevitzkiAlexa...lld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:GoldbergIrisIlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:KerenPninaPlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:RothArieAlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:BarshackIrisIlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:BinerSimonSlld:pubmed
pubmed-article:12782020pubmed:authorpubmed-author:SherezJackJlld:pubmed
pubmed-article:12782020pubmed:issnTypePrintlld:pubmed
pubmed-article:12782020pubmed:volume74lld:pubmed
pubmed-article:12782020pubmed:ownerNLMlld:pubmed
pubmed-article:12782020pubmed:authorsCompleteYlld:pubmed
pubmed-article:12782020pubmed:pagination314-8lld:pubmed
pubmed-article:12782020pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:meshHeadingpubmed-meshheading:12782020...lld:pubmed
pubmed-article:12782020pubmed:year2003lld:pubmed
pubmed-article:12782020pubmed:articleTitleTyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat.lld:pubmed
pubmed-article:12782020pubmed:affiliationDepartment of Cardiology and the Cardiovascular Research Laboratory, Tel-Aviv Medical Center, Tel-Aviv, Israel. jacobg@post.tau.ac.illld:pubmed
pubmed-article:12782020pubmed:publicationTypeJournal Articlelld:pubmed